ELK-1 activation has been reported to demonstrate pro-apoptotic activity within the cytoplasm and pro-differentiation activity inside the nucleus of cancer cells, which lowers aggressive cell proliferation.37 The degradation products of silodosin also exhibited anticancer activity.38 Hence, silodosin could be repurposed as an anti-NSCLCdrug. This evidence concerns the gene ELK1 and cancer.